Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

58.88USD
24 Mar 2017
Change (% chg)

$0.20 (+0.34%)
Prev Close
$58.68
Open
$59.03
Day's High
$59.80
Day's Low
$58.13
Volume
789,391
Avg. Vol
851,456
52-wk High
$62.50
52-wk Low
$30.00

ALKS.O

Chart for ALKS.O

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.20
Market Cap(Mil.): $8,951.48
Shares Outstanding(Mil.): 152.55
Dividend: --
Yield (%): --

Financials

  ALKS.O Industry Sector
P/E (TTM): -- 47.82 29.72
EPS (TTM): -1.38 -- --
ROI: -13.30 -2.46 13.00
ROE: -16.52 5.18 14.15

BRIEF-Alkermes Q4 non-gaap earnings per share $0.15

* Alkermes plc reports financial results for the year ended dec. 31, 2016 and provides financial expectations for 2017

Feb 15 2017

BRIEF-Alkermes inspiration grants awarded to support people affected by mental health and substance use disorders

* Alkermes inspiration grants(tm) awarded to support people affected by mental health and substance use disorders Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Alkermes Q3 loss per share $0.41

* Alkermes plc qtrly royalty revenue from Bydureon was $11.6 million, compared to $13.0 million for same period in prior year

Nov 02 2016

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Oct 21 2016

Alkermes depression drug succeeds in key trial; shares surge

Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Oct 20 2016

UPDATE 2-Alkermes depression drug succeeds in key trial; shares surge

Oct 20 Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Oct 20 2016

Alkermes depression drug meets main goal; shares surge

Oct 20 Alkermes Plc said its lead depression drug met the main goal of a late-stage trial, sending its shares up 48 pct in extended trading.

Oct 20 2016

BRIEF-Alkermes announces topline results from phase 3 study of Alks 5461

* Alkermes announces positive topline results from forward-5 pivotal phase 3 study of alks 5461 for major depressive disorder

Oct 20 2016

BRIEF-Alkermes, certain subsidiaries enter into amendment to amended, restated credit agreement

* Alkermes - On Oct. 12, co, certain other subsidiaries of company entered into an amendment to amended and restated credit agreement - SEC filing

Oct 13 2016

More From Around the Web

Competitors

Earnings vs. Estimates